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1
Highlights:2
3
4
 The proposed method allows to determine 39 antibiotics in liver simultaneously;5
 Validation process shows the good performance of the method;6
 The present method is a huge improvement for laboratories involved in food 7
safety control. 8
9
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36
Abstract37
38
A multiresidue quantitative screening method covering 39 antibiotics from 7 different 39
families by Ultra-High-Pressure-Liquid-Chromatography tandem Mass Spectrometry 40
(UHPLC-MS/MS) is described. Sulfonamides, trimethoprim, tetracyclines, macrolides, 41
quinolones, penicillins and chloramphenicol are simultaneously detected in liver tissue. 42
A simple sample treatment method consisting of extraction with a mixture of 43
acetonitrile and ethylenediaminetetraacetic acid (EDTA) followed by solid-phase 44
extraction (SPE) with a hydrophilic-lipophilic balanced (HLB) cartridge was developed.45
The methodology was validated, in accordance with Decision 2002/657/EC, by 46
evaluating the following required parameters: decision limit (CCα), detection capability 47
(CCβ), specificity, repeatability and reproducibility. The precision, in terms of the 48
relative standard deviation, was under 22% for all of the compounds, and the recoveries 49
were between 80% and 110%. The CCα and CCβ were determined according to the 50
maximum residue limit (MRL) or th  minimum required performance limit (MRPL),51
when established. 52
53
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1. Introduction59
60
Antibiotics are widely used for therapeutic and prophylactic purposes in food-producing 61
animals and to promote animal growth [1]. The use of antibiotics as growth promoters is 62
considered fraudulent in Europe because it can lead to residues of these compounds63
persisting in edible matrices. These antibiotic residues can result in allergic reactions in 64
some hypersensitive individuals and in the appearance of bacterial strains that are 65
resistant to drugs that are used in both veterinary and human medicine [2], which is 66
currently considered a huge worldwide concern.67
For that reason, the European Community determined the need for the mandatory 68
control of the veterinary drugs in food from animal origin designated for human 69
consumption [3]. For permitted veterinary drugs, the maximum residue limits (MRL) in 70
foodstuff of animal origin were established and are listed in the EU Commission 71
Regulation 37/2010 [4, 5].  Food products containing concentrations of antibiotics 72
exceeding the established MRL are inappropriate for human consumption. In the case of 73
some non-authorized substances, a minimum required performance limit (MRPL) has74
been set to harmonize the analytical performance of the methods used in different 75
laboratories [6, 7].76
A wide variety of edible matrices must be monitored for the presence of veterinary77
residues, including muscle, liver, kidney, fat, milk, eggs, fish and honey. Nevertheless, 78
there are relatively few multidetection and multiclass methods for the determination of 79
antibiotics in liver tissue. There are still very few methods describing approaches for 80
analyzing different classes of compounds, particularly for their determination in liver 81
tissue [8, 9]. To our knowledge, the only available method for the determination of an 82
extensive number of antibiotics from several classes in such a matrix was published by 83
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Kaufmann et al [8], who detected 100 veterinary drugs in muscle, liver and kidney 84
tissues using UPLC-ToF-MS. The main constraint with using ToF-MS methodologies is 85
related to the fact that it is impossible to use them for confirmation purposes because 86
ToF-MS is not yet included in the regulations [6]. 87
There are also some methods that group a few families of compounds, such as the one88
presented by Shao et al. [9], who developed a multiclass confirmatory method for 89
tetracyclines and quinolones in muscle, liver and kidney tissues using UHPLC-MS/MS.90
However, the common procedures described in the literature for the determination of 91
antibiotics in liver tissue only include groups of related compounds [10-14]92
When working with liver tissue and developing the sample preparation methodology, 93
one of the principal obstacles is related to the complexity associated with the high 94
protein and fat contents in this matrix, which often interfere in the analytical 95
performance. Additionally, the high enzymatic activity in liver tissue can be responsible 96
for the fast degradation of labile compounds, which leads to significant losses during 97
sample preparation. Another issue to be considered is that the simultaneous 98
determination of antibiotics from different pharmacologic families in complex 99
biological matrices is constrained by differences in the physicochemical properties of 100
the compounds [15, 16], a fact that makes developing the sample extraction method a 101
challenge that can only be overcome by reaching a compromise that better fits the 102
purpose of the multiclass method.103
The lack of methodologies for screening of antibiotics in liver demanded for new 104
developments in order to fulfill the requirements of the control program and, 105
consequently, improve food safety. Considering all of these aspects and the need for a 106
reliable and efficient method for the determination of antibiotics in liver tissue while107
improving the time of analysis for several groups of compounds and the cost-108
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effectiveness, the aim of this work was to develop a multiclass and multidetection 109
method using UHPLC-MS/MS for the detection of antibiotics from seven families 110
(sulfonamides, trimethoprim, tetracyclines, macrolides, quinolones, penicillins and 111
chloramphenicol). To use the method in routine analysis and official control, it was 112
validated according the requirements described in the European Commission Decision 113
2002/657/EC [6].114
115
2. Material and Methods116
117
2.1. Reagents, Solvents and Standard Solutions118
All of the reagents and solvents used were of analytical grade, with the exception of the 119
chemicals used for the mobile phase, which were of high-performance liquid 120
chromatography grade. Methanol, acetonitrile, n-hexane and formic acid were supplied 121
by Merck (Darmstadt, Germany). Ethylenediaminetetraacetic acid (EDTA) was 122
purchased from Sigma-Aldrich (Madrid, Spain). All of the standards of the 123
sulfonamides, tetracyclines, penicillins, macrolides, quinolones, trimethoprim and 124
chloramphenicol were supplied by Sigma-Aldrich (Madrid, Spain). The individual 125
standards are listed in Table 1. The following six internal standards were used: 126
demethyltetracycline for the tetracyclines; penicillin V for the penicillins; lomefloxacin 127
for the quinolones; roxithromycin for the macrolides; sulfameter for the sulfonamides 128
and trimethoprim; and chloramphenicol-fifth-deuterated (d5) for chloramphenicol. All 129
of the internal standards were provided by Sigma-Aldrich. For all of the substances, 130
stock solutions of 1 mg mL-1 were prepared by weighing the appropriate amount of 131
standard, diluting it in methanol, and storing it at -20°C for one year. Suitable dilutions 132
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were also prepared to have convenient spiking solutions for both the validation process 133
and the routine analyses. Working solutions were stored at -20ºC for one month.134
135
2.2. Instrumentation136
For the sample preparation, the following equipment was used: Mettler Toledo PC200 137
and AE100 balances (Greifensee, Switzerland), a Heidolph Reax 2 overhead mixer 138
(Schwabach, Germany), a Heraeus Megafuge 1.0 centrifuge (Hanau, Germany), a 139
Turbovap Zymark Evaporator (Hopkinton, MA, USA) and Whatman Mini-Uniprep 140
PVDF 0.45 µm filters (Clifton, NJ, USA). A vacuum manifold was used for the solid 141
phase extraction (SPE) with an Oasis HLB polymeric sorbent cartridge (3 mL, 200 mg) 142
(Waters, Milford, MA, USA). Chromatographic separation and mass spectrometry 143
detection were performed using a Xevo TQ MS–Acquity UPLC system coupled to a 144
triple quadrupole tandem mass spectrometer from Waters (Milford, MA, USA). The 145
electrospray ion source (ESI) was used both in positive and negative modes with data 146
acquisition in the multiple reaction monitoring mode (MRM), and the Masslynx 4.1 147
software (Waters) was used for data processing. The MRM optimized conditions are 148
presented in Table 1. The UHPLC system consisted of a vacuum degasser, an 149
autosampler and a binary pump equipped with an analytical reverse-phase column 150
(Acquity HSS T3 2.1 x 100 mm with 1.8 μm particle size, Waters). A flow rate of 0.45 151
mL min-1 was used with the following mobile phases: [A] formic acid 0.1% (v/v) in 152
water and [B] acetonitrile. The following gradient program was used: 0-5 min from 153
97% to 40% [A]; 5-9 min from 40% to 0% [A]; 9-10 min from 0% back to 97% [A]; 154
11-12 min 97% [A].  Column and autosampler were maintained at 40ºC and 10ºC, 155
respectively. A 20 µL aliquot (full loop) was injected onto the analytical column.156
157
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2.3. Sample preparation158
Two grams of minced and mixed liver tissue was weighed into a 20 mL glass centrifuge 159
tube. The internal standard solution was added, and the sample was vortexed for 30 s 160
and allowed to stand in the dark for at least 10 min. The sample was extracted by 161
shaking using a Reax shaker for 10 min with 10 mL of acetonitrile and 1 mL of 0.1 M 162
EDTA. After that, the sample was left in the ultrasound bath for 20 min. Following 163
centrifugation for 10 min at 4000×g, the supernatant was transferred into a new tube and 164
evaporated to near dryness (1 mL). Water (5 mL) was added, and the solution was 165
vortexed for 15 s. The solutions were then submitted to a clean-up step using SPE Oasis166
HLB cartridges, which were preconditioned with acetonitrile (10 mL) and water (10167
mL). After passing the aqueous extract through the columns using gravity, the 168
cartridges were washed with water (5 mL) and then dried under reduced pressure for 169
approximately 5 min. The elution was performed with acetonitrile (10 mL). The eluate 170
was evaporated to near dryness (0.5 mL) under a gentle stream of nitrogen and 400 μL 171
of mobile phase [A] was added. To this extract n-hexane (2 mL) was added and the 172
solution vortexed for 30 s. After centrifugation for 10 min at 4000×g, the n-hexane layer 173
was removed. The final extract was filtered through a 0.45 µm PVDF Mini-uniprep TM,174
transferred to vials and analyzed by UHPLC-MS/MS under the MRM optimized 175
conditions described in Table 1.176
177
2.4. Validation procedure178
In-house validation was performed following the method described by the EU 179
Commission Decision 2002/657/EEC [6] that requires the evaluation of the method in 180
terms of the specificity, recovery, repeatability, reproducibility, decision limit (CCα) 181
and detection capability (CCβ). 182
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By analyzing 20 blank liver samples from different animal species (bovine, swine, 183
ovine, and poultry) to find possible peaks that could interfere with the detection of the 184
target analytes, the specificity of the method was assessed. Afterwards, the same 20 185
samples were spiked with all of the compounds of interest at the validation level (VL)186
(Table 2) to prove the identification capability of the method and once again its 187
specificity. Calibration curves using spiked samples were assembled using the following 188
five concentration levels, 0.5xVL, 1.0xVL, 1.5xVL, 2.0xVL and 3.0xVL, and the 189
analyses were carried out on three different days with different operators. Six replicates 190
of the 0.5xVL, 1.0xVL and 1.5xVL concentration levels were performed each day to 191
determine the precision of the method (in terms of the repeatability and reproducibility) 192
and the recovery. The recovery was estimated as a ratio between the obtained193
concentration and the real concentration.194
The critical concentrations, CCα and CCβ, were calculated according to the following 195
equations [6]:196
    (Equation 1, for compounds without MRLs)197
    (Equation 2, for compounds with established MRLs)198
  (Equation 3)199
where μN is the mean of the noise amplitude of twenty blank samples; σN is the standard 200
deviation of the noise amplitude of twenty blank samples at the retention time of the 201
target analyte; and σMRL or σVL is the standard deviation at the MRL or VL level in the 202
twenty spiked blank samples at that level. For all of the determinations, the peak areas 203
of both the analytes and the corresponding internal standards were measured, and the 204
analyte/internal standard area ratios were determined. Internal standards were chosen 205
for their similar physicochemical behaviors to those of the antibiotics being monitored 206
[17].207
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208
3. Results and discussion209
The major challenge in the determination of veterinary drugs in biological samples, 210
usually in residual concentrations, lies in sample preparation. Our knowledge and 211
experience from previously developed multiclass methods in milk, fish and bovine 212
muscle [17-19] was the starting point for the present method. In these previously work, 213
the appropriated solvents, for the extraction of the target compound, were already 214
studied and, starting from that knowledge, a new method, to be used in liver, was 215
developed.  Thus, the best option for use as the extraction solvent, in terms of the 216
recovery, is an organic extractant, specifically acetonitrile. Aqueous solvents failed to 217
extract the less polar compounds. The same conclusion is expressed in other available 218
publications, though those extractions were performed on different matrices [8, 20],219
where acetonitrile is preferred over methanol and ethyl acetate, because these last two 220
solvents can be responsible for extracting matrix components that can interfere in the 221
detection. Additionally, it is important to add that acetonitrile, aside from being an 222
efficient extraction solvent, promotes the precipitation of proteins, thereby turning this223
step into one that is important for obtaining a clean extract. Some of the target 224
antibiotics, such as tetracyclines, quinolones and macrolides, can easily form chelate225
complexes with bi- and trivalent metal cations present in the sample extraction solution. 226
These can lead to lower recoveries; to prevent their formation, a chelate agent with a 227
similar behavior should be used to control the problem and increase the recoveries. For 228
that reason, EDTA is often used during the liquid extraction, and it has been determined229
to improve the extraction efficiencies of tetracyclines, quinolones and macrolides.230
Compared with muscle tissue, liver tissue is a much more complex matrix because of its 231
high protein content, enzymatic activity and fat content. Therefore, to prevent possible 232
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chromatographic interferences and ion suppression or enhancement, further clean-up 233
steps during the sample preparation were optimized. 234
The use of solid-phase extraction prior to mass spectrometric detection can be a huge 235
advantage to decrease the effects of ion suppression caused by components of liver236
tissue. To control the possible losses of target antibiotics, the best option is to use a 237
multiclass selectivity cartridge that can fit the diverse physicochemical properties of all238
of the target antibiotics. The best option, in terms of selectivity, is to use a sorbent 239
composed of a hydrophilic-lipophilic balance modified polymer (OASIS HLB), which 240
is known to have a very broad selectivity for polar compounds [8, 21]. The solid-phase 241
extraction is followed by concentration through evaporation under a gentle stream of 242
nitrogen, without evaporation to total dryness, to avoid a long evaporation process. The 243
instability of antibiotics along with the higher affinity of some polar compounds for 244
aqueous phase possibly remaining present in the cartridge and being eluted together 245
with the acetonitrile are the main reasons for this procedure [22]. After reconstitution 246
with the mobile phase, a thin lipidic layer was observed. To remove that layer and 247
prevent such interference in the mass spectrometric detection, a deffating step was 248
performed via the addition of n-hexane. After discarding the n-hexane layer, the final 249
extract was injected and analyzed using UHPLC-MS/MS.250
The UHPLC-MS/MS parameters, in terms of chromatography and detection, were 251
previously optimized. The mobile phase, flow rate and gradient steps were selected to252
achieve the best chromatographic separation and peak shape, along with a short run 253
time. The conditions described above allowed the determination of the 39 compounds in 254
less than 10 min. To fulfill the identification criteria described in Decision 2002/657 [6], 255
two ion transitions must be controlled for each compound. The ideal MRM conditions256
(Table 1) were achieved through the direct infusion into the detector of each individual 257
Page 12 of 21
Ac
ce
pte
d M
an
us
cri
pt
12
standard solution at a concentration of 10 μg mL-1. For positive ionization, which is the 258
case for all of the compounds except chloramphenicol, the use of formic acid in the 259
mobile phase works as a promoter of positive ionization and consequently improves the 260
detection. In Figure 1, individual MRM chromatograms of one compound per family of 261
monitored antibiotics obtained from a spiked bovine liver sample at the corresponding 262
validation level (VL) are presented.263
The method was validated in accordance with the European Commission Decision 264
2002/657/EC [6], and the following parameters were evaluated: specificity, recovery, 265
precision (as repeatability and reproducibility) decision limit (CCα) and detection 266
capability (CCβ). 267
The specificity of the method was assessed by analyzing 20 blank samples of liver268
tissue of different species (bovine, swine, ovine, and poultry) to verify the absence of 269
interference above a signal-to-noise ratio of 3 at the retention time of the target 270
compounds that could compromise their detection and identification. Additionally, in 271
the spiked blank samples, all of the identification criteria [6] were fulfilled without any 272
false negative results, again proving the specificity of the method for the species 273
analyzed. Considering the proved specificity and that no major differences were found 274
between the 20 blank and spiked samples, only one animal species (bovine) was used 275
for the next validation steps. This choice was based on the fact that bovine liver tissue is 276
a matrix that is very often consumed.277
The results obtained for the precision (repeatability and reproducibility) as the relative 278
standard deviation (RSD), recovery, CCα and CCβ are summarized in Table 2. The 279
precision and recovery were calculated at the VL that corresponds to the MRL for those 280
compounds that had it. For repeatability and reproducibility, the highest RSDs of 16% 281
and 24%, respectively, were obtained for sulfisoxazole. All of the other compounds had 282
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RSDs under these values. The recovery was calculated as a ratio between the 283
determined concentration in a spiked sample and the real concentration. The range of 284
values obtained were between 81 and 110%, thus falling into the acceptable range [6]. 285
Both the precision and recovery are mandatory parameters in validation because they286
measure the variability during the analytical process and can be used to analyze and 287
prove the robustness of the method.288
The two critical concentrations, CCα and CCβ, were determined from the calibration 289
curves obtained from the bovine blank liver samples spiked at five concentration levels 290
(0.5, 1, 1.5, 2  and 3xVL) and the application of the equations described above 291
(equations 1, 2 and 3), keeping in mind that not all of the compounds had an established292
MRL. Antibiotics without a tolerance level (MRL) had lower CCα and CCβ values that 293
were closer to the limit of detection of the method, although in the other cases, these 294
concentrations were always above the MRL.295
296
297
4. Conclusions298
An analytical method is proposed for the simultaneous determination of 39 antibiotics299
from 7 different classes in liver tissue. The developed method is able to determine the 300
presence of compounds from the sulfonamides, tetracyclines, macrolides, quinolones, 301
chloramphenicol, penicillins and trimethoprim in a single run using UHPLC-MS/MS, 302
providing a possible way to significantly reduce the time required to analyze one 303
sample. The developed method was fully validated and fulfilled all of the criteria 304
specified by the European Union Decision 2002/657/EC [6], proving that it is suitable 305
for routine analysis and quantitative screening purposes for official control, with the 306
possibility of extending the method for antibiotic confirmation. Although the main part 307
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of the validation procedure was performed only for bovine samples, its specificity 308
proved that the method can be used for swine, ovine and poultry liver tissue.309
Because there are a limited number of publications reporting methods for the 310
simultaneous analysis of antibiotics in liver tissue, the present method is a huge 311
improvement for laboratories that are involved in food safety control and have a large 312
number of samples and antibiotics to analyze. 313
314
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Table 1 – Multiple reaction monitoring (MRM) acquisition conditions for each antibiotic and for the 421
internal standards (IS) used.422
423
424
425
ESI
Precursor 
ion (m/z)
Product 
ions (m/z)
Cone 
voltage 
(V)
Collision 
energy (eV)
sulfapyridine + 250.3 156.3/92.3 30 15
sulfadiazine + 251.2 156.2/92.2 30 15
sulfamethoxazole + 254.4 156.4/92.2 30 20
sulfathiazole + 256.4 156.3/92.3 25 15
sulfisoxazole + 268.3 156.2/113.2 25 15
sulfamethiazole + 271.0 156.2/108.1 25 15
sulfisomidine + 279.4 186.3/124.4 30 16
sulfamethazine + 279.4 156.3/124.5 30 15
sulfamethoxypyridazine + 281.2 156.2/92.2 30 15
sulfachloropyridazine + 285.3 92.3/156.3 30 28
sulfadoxine + 311.4 156.4/92.3 30 18
sulfadimethoxine + 311.4 156.4/92.3 30 20
sulfanilamide + 173.2 92.1/156.2 30 25
sulfaquinoxaline + 301.3 92.2/156.3 30 30
Sulfonamides
sulfameter (IS) + 281.3 92.2 25 30
trimethoprim + 291.5 230.3/261.3 25 23
tetracycline + 445.5 410.3/427.3 25 20
doxycycline + 445.5 428.2/410.3 25 18
oxytetracycline + 461.5 426.3/443.3 25 20
chlorotetracycline + 479.3 444.2/462.1 25 20
Tetracyclines
demethyltetracycline (IS) + 465.2 448.3 25 17
erythromycin + 734.5 158.2/576.5 25 30
spyriamicin + 843.5 174.0/540.3 35 35
tilmicosin + 869.3 174.2/156.1 35 45
tylosin + 917.1 174.3/772.5 35 35
Macrolides
roxithromycin (IS) + 837.7 679.5 30 30
nalidixic acid + 233.2 215.1/187.1 40 14
flumequine + 262.2 202.1/244.2 30 32
oxolinic acid + 262.2 216.1/244.2 30 25
cinoxacin + 263.2 217.1/245.2 30 23
norfloxacin + 320.3 276.2233.2 20 17
enoxacin + 321.2 303.2/234.2 35 18
ciprofloxacin + 332.2 288.2/245.2 35 17
danofloxacin + 358.3 96.1/314.3 33 21
enrofloxacin + 360.3 316.3/245.2 31 19
ofloxacin + 362.1 261.3/318.2 34 26
marbofloxacin + 363.3 72.1/320.2 30 20
Quinolones
lomefloxacin (IS) + 352.2 265.3 31 22
amoxicillin + 366.3 160.3/114.4 25 20
oxacillin + 402.0 243.0/160.0 30 20
nafcillin + 415.0 199.0/171.0 30 25
dicloxacillin + 470.0 311.0/160.0 30 25
Penicillins
penicillin V (IS) + 351.0 160.2 25 25
chloramphenicol - 320.9 151.9/193.9 30 25
Amphenicol
chloramphenicol-d5 (IS) - 326.0 157.0 30 25
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Table 2 – Maximum Residue Levels (MRLs) set by European Union for liver tissue, 425
validation level (VL) and validation parameters: decision limit (ccα), detection 426
capability (ccβ), repeatability, reproducibility and recovery.427
MRL
(μg kg-1)
VL
(μg kg-1)
CCα
(μg kg-1)
CCβ
(μg kg-1)
Repeatability 
(%RSD)
Reproducibility 
(%RSD)
Recovery 
(%)
sulfapyridine 100 100 124 149 15 22 101
sulfadiazine 100 100 125 150 15 22 105
sulfamethoxazole 100 100 121 142 15 23 85
sulfathiazole 100 100 115 129 8 12 109
sulfisoxazole 100 100 123 146 16 24 88
sulfamethiazole 100 100 111 122 6 9 108
sulfisomidine 100 100 123 146 13 19 108
sulfamethazine 100 100 115 129 8 12 110
sulfamethoxypyridazine 100 100 114 129 8 12 110
sulfachloropyridazine 100 100 118 135 10 15 107
sulfadoxine 100 100 111 123 7 11 97
sulfadimethoxine 100 100 123 147 13 19 110
sulfanilamide 100 100 125 150 15 22 105
sulfaquinoxaline 100 100 118 137 11 17 98
trimethoprim 50 50 65 81 11 16 88
tetracycline 300 300 322 343 12 18 109
doxycycline 300 300 325 351 14 22 108
oxytetracycline 300 300 313 326 7 11 110
chlorotetracycline 300 300 321 343 15 22 88
erythromycin 200 200 219 237 10 16 109
spyriamicin 300 300 317 333 10 15 102
tilmicosin 1000 1000 1024 1048 13 20 110
tylosin 100 100 111 122 7 10 101
nalidixic acid - 100 5.81 16.0 15 23 110
flumequine 500 500 528 555 15 23 110
oxolinic acid 150 150 166 182 9 13 109
cinoxacin - 100 3.10 7.60 15 22 100
norfloxacin - 100 0.32 0.94 13 19 108
enoxacin - 100 1.72 3.87 15 22 88
ciprofloxacin 300 300 316 331 11 17 87
danofloxacin 400 400 418 437 12 18 94
enrofloxacin 300 300 325 349 15 22 103
ofloxacin - 100 0.22 0.65 8 13 81
marbofloxacin 150 150 174 198 14 21 107
amoxicillin 50 50 74 97 15 22 98
oxacillin 300 300 320 339 14 22 83
nafcillin 300 300 321 341 12 17 109
dicloxacillin 300 300 325 349 14 21 109
chloramphenicol - 0.3 0.28 0.48 11 17 109
428
429
430
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Figure 1: Individual MRM of one antibiotic per family is given as example from a 430
spiked liver sample at the corresponding validation level (100 µgkg-1 for sulfanilamide 431
and tylosin; 50 µgkg-1 for trimethoprim and amoxicillin; 300 µgkg-1 for oxitetracycline; 432
0.3 µgkg-1 for chloramphenicol and 500 µgkg-1 for flumequine). 433
434
435
